The Impact of Preclinical High Potent P2Y<sub>12</sub> Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome

The Impact of Preclinical High Potent P2Y<sub>12</sub> Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome

Background: Purinergic signaling receptor Y<sub>12</sub> (P2Y<sub>12</sub>) inhibitors are a fundamental part of pharmacological therapy in acute coronary syndrome (ACS) for preventing recurrent ischemic events. Current guidelines support the use of prasugrel over ticagrelor—...

Full description

Bibliographic Details
Main Authors: Andreas Hammer, Mario Krammel, Patrick Aigner, Georg Pfenneberger, Sebastian Schnaubelt, Felix Hofer, Niema Kazem, Lorenz Koller, Eva Steinacher, Ulrike Baumer, Christian Hengstenberg, Alexander Niessner, Patrick Sulzgruber
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Journal of Clinical Medicine
Subjects:
P2Y12 inhibitor loading
acute coronary syndrome
ticagrelor
prasugrel
STEMI
cardiovascular mortality
Online Access:https://www.mdpi.com/2077-0383/12/12/4094

Internet

https://www.mdpi.com/2077-0383/12/12/4094

Similar Items